Mizuho has revised its price target for Hologic (HOLX, Financial), reducing it from $83 to $75, while maintaining an Outperform rating on the stock. This adjustment comes as part of the firm's first-quarter preview for the medical devices and diagnostics sector.
The revision reflects concerns over several critical factors impacting the company's upcoming performance. Key issues include the implications of tariffs, Hologic's exposure to the Chinese market, and the latest industry procedures outlook. Mizuho preemptively adjusted its forecasts in anticipation of these challenges, demonstrating a cautious approach as the quarter progresses.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Hologic Inc (HOLX, Financial) is $77.16 with a high estimate of $90.00 and a low estimate of $65.00. The average target implies an upside of 33.36% from the current price of $57.86. More detailed estimate data can be found on the Hologic Inc (HOLX) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Hologic Inc's (HOLX, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Hologic Inc (HOLX, Financial) in one year is $80.37, suggesting a upside of 38.9% from the current price of $57.86. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Hologic Inc (HOLX) Summary page.
